The Imaging Response Assessment Team (IRAT) is a shared resource providing image-based tumor metrics for cancer research, as one of a national consortium of cancer center IRATs. The IRAT serves as a key component of investigator-initiated, cooperative group and industry-sponsored clinical trials at Moffitt, providing quantitative size-based measurements of tumor response. Year-to-year increases in the volume of service have generated the need for a cost center to support and institutionalize the Moffitt IRAT. The present proposal seeks to expand the capabilities and scope of this IRAT to support the infrastructure necessary for investigator-initiated studies at Moffitt.
The specific aims for the current effort are to support the IRAT infrastructure, which is used to: 1) Maintain the current quality of reported quantitative data and rapid response time;2) Expand the quantitative nature of reporting through more detailed image analysis;3) Coordinate acquisition and analysis of radiological images in support of clinical trials;4) Consult in clinical trials protocol submission;5) Review clinical trials in Scientific Review Committee;6) Provide pilot data for grant submissions;7) Assist in development of non-traditional imaging endpoints for response assessment, including participation in ACRIN and COG trials;and 8) Educate and reach out to Moffitt oncologists and investigators to increase awareness of new horizons in cancer imaging. These achievements are critical to accommodate the increasing complexity and importance of imaging biomarkers in response assessment, as the limitations and inadequacies of conventional metrics are recognized. An expansion of IRAT personnel is an immediate need to realize these goals. In 2009, 169 clinical trials with a primary imaging endpoint to assess tumor response were active, with the majority originating from the Experimental Therapeutics program, followed by Immunology. Of these, 71 were investigator-initiated, non-Industrial Moffitt or cooperative trials, and 94 had new patient accrual in 2009. These clinical trials spanned the breadth of Oncology Groups at Moffitt. The Core requests CCSG support of $153,973 which is 39% of its operational budget.

Public Health Relevance

The IRAT adds value to the CC mission by streamlining the process of integrating imaging into trials and providing QA/QC throughout the process, especially for trials not initiated by radiologists. Developing an infrastructure for the IRAT has permitted the pursuit of other funded trial opportunities that use advanced and/or investigational imaging techniques, analysis, and novel biomarkers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-16
Application #
8613460
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$65,400
Indirect Cost
$26,587
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612
Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53
Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303
Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73
Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :
Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880
Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029
Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :
Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96

Showing the most recent 10 out of 974 publications